Trihexyphenidyl treatment of clozapine-induced hypersalivation.

Abstract

The objective of this study was to investigate the efficacy of the anticholinergic agent trihexyphenidyl in the treatment of clozapine-induced hypersalivation. Fourteen chronic schizophrenic patients who exhibited nocturnal hypersalivation during clozapine treatment were coadministered trihexyphenidyl (5-15 mg/day, at bedtime) for 15 days. Salivation was assessed by a single-item 5-point scale. A reduction of 44% in the reported nocturnal hypersalivation was observed after trihexyphenidyl treatment. These results indicate that at least some chronic schizophrenic patients with clozapine-induced nocturnal hypersalivation may benefit from anticholinergic treatment.

• Authors: B Spivak, S Adlersberg, L Rosen, N Gonen, R Mester, A Weizman
• Journal: International clinical psychopharmacology (Int Clin Psychopharmacol) Vol. 12 Issue 4 Pg. 213-5 (Jul 1997) ISSN: 0268-1315 [Print] England
• PMID: 9347382 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antipsychotic Agents
• Muscarinic Antagonists
• Trihexyphenidyl
• Clozapine

Topics

• Adult
• Antipsychotic Agents (adverse effects)
• Clozapine (adverse effects)
• Female
• Humans
• Male
• Muscarinic Antagonists (therapeutic use)
• Schizophrenia (drug therapy)
• Sialorrhea (chemically induced, drug therapy)
• Trihexyphenidyl (therapeutic use)